<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05102838</url>
  </required_header>
  <id_info>
    <org_study_id>Spark Srudy</org_study_id>
    <nct_id>NCT05102838</nct_id>
  </id_info>
  <brief_title>Prospective Cohort Study on Prognosis of Patients With Hepatitis B/C</brief_title>
  <official_title>Prospective Cohort Study on Prognosis of Patients With Hepatitis B/C in Hainan Province Danzhou City</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis B (HBV) and hepatitis C (HCV) are prevalent all over the world, which seriously&#xD;
      threatens public health. In 2016, the World Health Organization(WHO) put forward the goal of&#xD;
      eliminating the threat of viral hepatitis to public health by 2030. However, at present, the&#xD;
      diagnosis rate and treatment rate of chronic HBV and HCV in China are still far from the goal&#xD;
      put forward by WHO. Therefore, for China, the elimination of viral hepatitis is still a&#xD;
      public health problem that needs a long time to face.&#xD;
&#xD;
      This study aims to screen and follow up HBV and HCV patients in Danzhou City, Hainan&#xD;
      Province, so as to understand the epidemiological characteristics and long-term prognosis of&#xD;
      HBV/HCV patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis B (HBV) and hepatitis C (HCV) are prevalent all over the world, which seriously&#xD;
      threatens public health. According to the survey, there are about 93 million chronic HBV&#xD;
      infected people and 10 million chronic HCV infected people in China, accounting for 36.19%&#xD;
      and 14.08% of the global HBV and HCV infected people respectively. Chronic HBV and HCV&#xD;
      infection is the main cause of liver cirrhosis and liver cancer, which places a great burden&#xD;
      on the national economy.&#xD;
&#xD;
      In 2016, the World Health Organization(WHO) put forward the goal of eliminating the threat of&#xD;
      viral hepatitis to public health by 2030, including 90% diagnosis rate, 80% treatment rate&#xD;
      and 90% cure rate of viral hepatitis, in order to reduce 65% of viral hepatitis related&#xD;
      deaths and reduce the disease burden. However, at present, the diagnosis rate of chronic HBV&#xD;
      in China is 18.7%, the treatment rate is 10.8%, the diagnosis rate of chronic HCV is 30%, and&#xD;
      the treatment rate is 9%, which are still far from the goal put forward by WHO. Therefore,&#xD;
      for China, the elimination of viral hepatitis is still a public health problem that needs a&#xD;
      long time to face.&#xD;
&#xD;
      This study aims to screen and follow up HBV and HCV patients in Danzhou City, Hainan&#xD;
      Province, so as to understand the epidemiological characteristics and long-term prognosis of&#xD;
      HBV/HCV patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Epidemiological characteristics of hepatitis B and C</measure>
    <time_frame>up to 192 weeks</time_frame>
    <description>Epidemiological characteristics of hepatitis B and C in Danzhou City, Hainan Province</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term outcome</measure>
    <time_frame>up to 192 weeks</time_frame>
    <description>Long-term outcome of HBV/HCV infected patients in Danzhou City, Hainan Province</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk factors</measure>
    <time_frame>up to 192 weeks</time_frame>
    <description>Risk factors for long-term outcome of HBV/HCV infected patients in Danzhou City, Hainan Province</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of cirrhosis</measure>
    <time_frame>up to 192 weeks</time_frame>
    <description>Incidence of cirrhosis for HBV/HCV infected patients in Danzhou City, Hainan Province</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of liver cancer</measure>
    <time_frame>up to 192 weeks</time_frame>
    <description>ncidence of liver cirrhosis for HBV/HCV infected patients in Danzhou City, Hainan Province</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic decompensation</measure>
    <time_frame>up to 192 weeks</time_frame>
    <description>Hepatic decompensation rate for HBV/HCV infected patients in Danzhou City, Hainan Province</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rate for liver cancer</measure>
    <time_frame>up to 192 weeks</time_frame>
    <description>Survival rate for liver cancer patients in Danzhou City, Hainan Province</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rate for cirrhosis</measure>
    <time_frame>up to 192 weeks</time_frame>
    <description>Survival rate for cirrhosis patients in Danzhou City, Hainan Province</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV interruption rate of perinatal transmission</measure>
    <time_frame>up to 192 weeks</time_frame>
    <description>HBV interruption rate of perinatal transmission in Danzhou City, Hainan Province</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg loss</measure>
    <time_frame>up to 192 weeks</time_frame>
    <description>The HBsAg loss rate of HBV infected patients in Danzhou City, Hainan Province</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">60000</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Hepatitis B cohort</arm_group_label>
    <description>Patients with HBsAg and/or HBV DNA positive;&#xD;
Patients without cirrhosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatitis C cohort</arm_group_label>
    <description>Patients with anti-HCV and/or HCV RNA positive;&#xD;
Patients without cirrhosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cirrhosis cohort</arm_group_label>
    <description>Patients diagnosised with cirrhosis;&#xD;
Patients with HBsAg, and/or HBV DNA, and/or anti-HCV and/or HCV RNA positive.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liver cancer cohort</arm_group_label>
    <description>Patients diagnosised with liver cancer;&#xD;
Patients with HBsAg, and/or HBV DNA, and/or anti-HCV and/or HCV RNA positive.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Anti-virus treatment</intervention_name>
    <description>Anti-virus treatment</description>
    <arm_group_label>Cirrhosis cohort</arm_group_label>
    <arm_group_label>Hepatitis B cohort</arm_group_label>
    <arm_group_label>Hepatitis C cohort</arm_group_label>
    <arm_group_label>Liver cancer cohort</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples will be retained at each timepoints.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hepatitis B or hepatitis C patients will be enrolled in this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HBsAg/HBV DNA positive&#xD;
&#xD;
          -  or anti-HCV/HCV RNA positive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients who refused to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bingliang Lin, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junfeng Chen, Dr.</last_name>
    <phone>86-20-85252363</phone>
    <email>mountainchen@139.com</email>
  </overall_contact>
  <reference>
    <citation>1.Lu FM, Zhuang H. Management of hepatitis B in China[J]. Chin Med J ( Engl) , 2009, 122(1): 3-4． 2.Chen YS, Li L, Cui FQ et al. Seroepidemiological study of hepatitis C in China[J].Chinese Journal of Epidemiology, 2011, 32:888-891. 3.Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China[J]. Hepatology, 2014, 60(6): 2099 -2108． 4.Huang YW, Yang SS, Fu SC, et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: a nationwide cohort study[J]. Patology, 2014,60:807-814. 5.69th World Health Assembly. Draft Global Health Sector Strategies. April 2016. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA69/A69_32-en.pdf?ua=1 (accessed February 2017) 6.Global Hepatitis Report, 2017. http://www.who.int/mediacentre/factsheets/fs164/zh. 7.CDA Foundation's Polaris Observatory; 2020 Available from https://cdafound.org/polaris/ (Accessed 2020-06-09).</citation>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Lin Bingliang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

